StockNews.com Begins Coverage on Ekso Bionics (NASDAQ:EKSO)

Investment analysts at StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a note issued to investors on Sunday. The firm set a “hold” rating on the stock.

EKSO has been the topic of several other research reports. Lake Street Capital reduced their price objective on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th. HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Ekso Bionics in a research report on Tuesday, January 14th.

Ekso Bionics Trading Down 2.6 %

Ekso Bionics stock opened at $0.55 on Friday. The stock has a market cap of $12.01 million, a P/E ratio of -0.84 and a beta of 1.46. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14. Ekso Bionics has a 1 year low of $0.47 and a 1 year high of $2.16. The firm’s 50 day moving average price is $0.63 and its 200-day moving average price is $0.84.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.